product name Megestrol Acetate
Description: Megestrol acetate (also known as BDH1298, SC10363) is a synthetic progestogen, used to treat breast cancer and loss of appetite. Megestrol Acetate could cause minor reduction of tumor size and prolonged survival time in Hepatocellular carcinoma (HCC). In addition, Megestrol Acetate has shown a dose-dependent inhibition on growth of the human liver tumor cells in the HepG2 cell lines with the IC50 value of 260μM in vitro. Furthermore, Megestrol Acetate has also shown a significant suppression of tumor growth.
References: Eur J Pharmacol. 2011 Mar 11;654(3):217-25; Aquat Toxicol. 2014 May;150:66-72.
384.51
Formula
C24H32O4
CAS No.
595-33-5
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 33 mg/mL (85.8 mM)
Water: <1 mg/mL
Ethanol: 15 mg/mL (39.0 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/1939499
| In Vitro |
In vitro activity: Megestrol acetate inhibits the expression of cytoplasmic aromatase through nuclear C/EBPβ in reperfusion injury-induced ischemic rat hippocampus. Megestrol acetate significantly increases the proliferation, migration, and adipogenic differentiation of adipose-derived stem cells (ASCs) in a dose-dependent manner. Megestrol acetate also upregulates genes downstream of glucocorticoid receptor (GR) in ASCs. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Megestrol acetate significantly decreases the circulating concentrations of estradiol (E2) and testosterone (T) in female fish or 11-ketotestosterone (11-KT) in male fish. Megestrol acetate exposure significantly downregulates the transcription of certain genes along the hypothalamic-pituitary-gonadal (HPG) axis. Megestrol acetate produces a progressive deterioration in glucose tolerance, with a significant increase in mean fasting plasma glucose concentrations and decrease in mean plasma glucose clearance rates after 6 months and 12 months of treatment in cats. Megestrol acetate also produces a progressive decrease in both resting plasma cortisol concentrations and cortisol concentrations after ACTH stimulation in cats. Megestrol acetate (50 mg/kg/day) for 9 days significantly increases food and water intake compared with untreated controls. Megestrol acetate (50 mg/kg/day) significantly (90-140%) increases in neuropeptide Y concentrations in the arcuate nucleus (where neuropeptide Y is synthesized), in the lateral hypothalamic area (through which arcuate neurones project) and in the medial preoptic area, ventromedial nucleus and dorsomedial nucleus in rats. |
| Animal model | |
| Formulation & Dosage | |
| References | Eur J Pharmacol. 2011 Mar 11;654(3):217-25; Aquat Toxicol. 2014 May;150:66-72. |
Related Posts
product name Megestrol Acetate
Description: Megestrol acetate (also known as BDH1298, SC10363) is a synthetic progestogen, used to treat breast cancer and loss of appetite. Megestrol Acetate could cause minor reduction of tumor size and prolonged survival time in Hepatocellular carcinoma (HCC). In addition, Megestrol Acetate has shown a dose-dependent inhibition on growth of the human liver tumor cells in the HepG2 cell lines with the IC50 value of 260μM in vitro. Furthermore, Megestrol Acetate has also shown a significant suppression of tumor growth.
References: Eur J Pharmacol. 2011 Mar 11;654(3):217-25; Aquat Toxicol. 2014 May;150:66-72.
384.51
Formula
C24H32O4
CAS No.
595-33-5
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 33 mg/mL (85.8 mM)
Water: <1 mg/mL
Ethanol: 15 mg/mL (39.0 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/1939499
| In Vitro |
In vitro activity: Megestrol acetate inhibits the expression of cytoplasmic aromatase through nuclear C/EBPβ in reperfusion injury-induced ischemic rat hippocampus. Megestrol acetate significantly increases the proliferation, migration, and adipogenic differentiation of adipose-derived stem cells (ASCs) in a dose-dependent manner. Megestrol acetate also upregulates genes downstream of glucocorticoid receptor (GR) in ASCs. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Megestrol acetate significantly decreases the circulating concentrations of estradiol (E2) and testosterone (T) in female fish or 11-ketotestosterone (11-KT) in male fish. Megestrol acetate exposure significantly downregulates the transcription of certain genes along the hypothalamic-pituitary-gonadal (HPG) axis. Megestrol acetate produces a progressive deterioration in glucose tolerance, with a significant increase in mean fasting plasma glucose concentrations and decrease in mean plasma glucose clearance rates after 6 months and 12 months of treatment in cats. Megestrol acetate also produces a progressive decrease in both resting plasma cortisol concentrations and cortisol concentrations after ACTH stimulation in cats. Megestrol acetate (50 mg/kg/day) for 9 days significantly increases food and water intake compared with untreated controls. Megestrol acetate (50 mg/kg/day) significantly (90-140%) increases in neuropeptide Y concentrations in the arcuate nucleus (where neuropeptide Y is synthesized), in the lateral hypothalamic area (through which arcuate neurones project) and in the medial preoptic area, ventromedial nucleus and dorsomedial nucleus in rats. |
| Animal model | |
| Formulation & Dosage | |
| References | Eur J Pharmacol. 2011 Mar 11;654(3):217-25; Aquat Toxicol. 2014 May;150:66-72. |